Literature DB >> 2471068

H-ras mutants lacking the epitope for the neutralizing monoclonal antibody Y13-259 show decreased biological activity and are deficient in GTPase-activating protein interaction.

S K Srivastava1, A Di Donato, J C Lacal.   

Abstract

We have generated deletion mutants of the H-ras p21 protein which lack residues 58 to 63 or 64 to 68 and contain either the normal glycine or an activating mutation, arginine, at position 12. None of the deleted proteins were recognized by monoclonal antibody Y13-259, and those mutants with activating mutations showed at least a 100-fold reduction in their transforming activities compared with the activities of their nondeleted counterparts. Alterations observed in the in vitro GTPase or GTP interchange properties of the deletion mutants were not consistent with the decrease in their transforming activities. Moreover, each mutant showed normal membrane localization, which is essential for its biological activity. Recently, a newly identified protein, designated GTPase-activating protein (GAP), was found to markedly increase GTPase activity of the normal ras p21 but not of p21 mutants bearing activating lesions (H. Adari, D. R. Lowy, B. M. Willumsen, C. J. Der, and F. McCormick, Science 240:518-521, 1988). We showed that GAP had no effect on the in vitro GTPase activity of the deletion mutants of the normal p21 protein. Since similar deletions in mutants with activating lesions at position 12 or 59 or both showed decreased transforming activity, our results suggest that the recognition site for Y13-259 within the ras p21 molecule influences directly or indirectly the interaction of ras p21 with GAP and that this interaction is critical for biological activity of ras proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471068      PMCID: PMC362597          DOI: 10.1128/mcb.9.4.1779-1783.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

1.  Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain.

Authors:  H Adari; D R Lowy; B M Willumsen; C J Der; F McCormick
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

2.  Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors.

Authors:  M J Zoller; M Smith
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

3.  Analysis of the transforming potential of the human H-ras gene by random mutagenesis.

Authors:  O Fasano; T Aldrich; F Tamanoi; E Taparowsky; M Furth; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Mechanism of activation of a human oncogene.

Authors:  C J Tabin; S M Bradley; C I Bargmann; R A Weinberg; A G Papageorge; E M Scolnick; R Dhar; D R Lowy; E H Chang
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

5.  Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene.

Authors:  Y Yuasa; S K Srivastava; C Y Dunn; J S Rhim; E P Reddy; S A Aaronson
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

6.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

7.  The p21 ras C-terminus is required for transformation and membrane association.

Authors:  B M Willumsen; A Christensen; N L Hubbert; A G Papageorge; D R Lowy
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

8.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

9.  The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product.

Authors:  C Calés; J F Hancock; C J Marshall; A Hall
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

10.  Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1.

Authors:  K Shimizu; D Birnbaum; M A Ruley; O Fasano; Y Suard; L Edlund; E Taparowsky; M Goldfarb; M Wigler
Journal:  Nature       Date:  1983 Aug 11-17       Impact factor: 49.962

View more
  3 in total

1.  Antibodies to synthetic peptide from the residue 33 to 42 domain of c-Ha-ras p21 block reconstitution of the protein with different effectors.

Authors:  I Rey; P Soubigou; L Debussche; C David; A Morgat; P E Bost; J F Mayaux; B Tocque
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

2.  Interaction of activated Ras with Raf-1 alone may be sufficient for transformation of rat2 cells.

Authors:  S Stang; D Bottorff; J C Stone
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

3.  Ras p21 in breast tissue: associations with pathology and cellular localisation.

Authors:  J J Going; T J Anderson; A H Wyllie
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.